Targeting Cellular Metabolism in Acute Myeloid Leukemia and The Role of Patient Heterogeneity.

ABSTRACT: Acute myeloid leukemia (AML) is an aggressive blood cancer resulting in accumulation of immature, dysfunctional blood cells in the bone marrow. Changes in cell metabolism are features of many cancers, including AML and this may be exploited as a therapeutic target. In this study we investigated the in vitro antileukemic effects of seven metabolic inhibitors that target different metabolic pathways. The metabolic inhibitors were tested on AML cells derived from 81 patients using proliferation and viability assays; we also compared global gene expression and proteomic profiles for various patient subsets. Metformin, 2DG, 6AN, BPTES and ST1326 had strong antiproliferative and proapoptotic effects for most patients, whereas lonidamine and AZD3965 had an effect only for a minority. Antiprolifer

SUBMITTER: Gronningsæter IS 

PROVIDER: S-EPMC7290417 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature